Cysteine engineered antibodies and conjugates
US-2015017188-A1 · Jan 15, 2015 · US
US11098052B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11098052-B2 |
| Application number | US-201716081683-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 2, 2017 |
| Priority date | Mar 2, 2016 |
| Publication date | Aug 24, 2021 |
| Grant date | Aug 24, 2021 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present disclosure relates to 4-azapodophylotoxins compounds, pharmaceutical compositions comprising such compounds, kits, and methods for using such compounds or pharmaceutical compositions.
Opening claim text (preview).
What is claimed is: 1. A compound selected from the group consisting of: 6,7-Methylenedioxy-4-(cyclobutyl)-9-(3,4,5-trimethoxyphenyl)-4,9-dihydro-3H-furo[3,4-b]quinolin-1-one (Compound 17); 6,7-Methylenedioxy-4-(cyclopentyl)-9-(3,4,5-trimethoxyphenyl)-4,9-dihydro-3H-furo[3,4-b]quinolin-1-one (Compound 18); 6,7-Methylenedioxy-4-(cyclohexyl)-9-(3,4,5-trimethoxyphenyl)-4,9-dihydro-3H-furo[3,4-b]quinolin-1-one (Compound 19); 6,7-Methylenedioxy-4-(2-piperidin-1-yl-ethyl)-9-(3,4,5-trimethoxyphenyl)-4,9-dihydro-3H-furo[3,4-b]quinolin-1-one (Compound 21); 6,7-Methylenedioxy-4-(2-morpholin-4-yl-ethyl)-9-(3,4,5-trimethoxyphenyl)-4,9-dihydro-3H-furo[3,4-b]quinolin-1-one (Compound 22); 6,7-Methylenedioxy-4-(cyclopentyl)-9-(4-hydroxy-3,5-dimethoxy-phenyl)-4,9-dihydro-3H-furo[3,4-b]quinolin-1-one (Compound 30); and a pharmaceutically acceptable salt thereof. 2. A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. 3. A method for treating cancer in a patient in need thereof comprising administering to the patient a compound of claim 1 , wherein the compound is administered in an amount effective to treat cancer. 4. The compound of claim 1 , wherein the compound is selected from the group consisting of: 6,7-Methylenedioxy-4-(cyclobutyl)-9-(3,4,5-trimethoxyphenyl)-4,9-dihydro-3H-furo[3,4-b]quinolin-1-one (Compound 17); 6,7-Methylenedioxy-4-(cyclopentyl)-9-(3,4,5-trimethoxyphenyl)-4,9-dihydro-3H-furo[3,4-b]quinolin-1-one (Compound 18); 6,7-Methylenedioxy-4-(cyclohexyl)-9-(3,4,5-trimethoxyphenyl)-4,9-dihydro-3H-furo[3,4-b]quinolin-1-one (Compound 19); 6,7-Methylenedioxy-4-(cyclopentyl)-9-(4-hydroxy-3,5-dimethoxy-phenyl)-4,9-dihydro-3H-furo[3,4-b]quinolin-1-one (Compound 30); and a pharmaceutically acceptable salt thereof.
Antineoplastic agents · CPC title
the condensed system containing two rings with oxygen as ring hetero atom and one ring with nitrogen as ring hetero atom · CPC title
Ortho-condensed systems · CPC title
the oxygen-containing ring being five-membered · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.